OMB No.: 0970–0430.

Description: The Child Care and Development Fund (CCDF) Tribal Annual Report (ACF–700) requests annual Tribal aggregate information on services provided through the CCDF, which is required by CCDF regulations (45 CFR parts 98 and 99). Tribal Lead Agencies (TLAs) are required to submit annual aggregate data appropriate to Tribal programs on children and families receiving CCDF-funded child care services. The revised ACF–700 report consists of two parts: (1) Administrative Data, and (2) Tribal Narrative. The content and format of the narrative section have been revised to make the form easier to complete, with check box formatting. These proposed revisions will allow the Office of Child Care (OCC) to more easily generate and quantify data in the report.

ANNUAL BURDEN ESTIMATES

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden hours per response</th>
<th>Total burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACF–700 Report</td>
<td>260</td>
<td>1</td>
<td>38</td>
<td>9,880</td>
</tr>
</tbody>
</table>

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[CFDA Number: 93.569]

Announcing the Award of a Single Source Expansion Supplement to Community Action Partnership in Washington, DC

AGENCY: Office of Community Services, ACF, HHS.

ACTION: Notice of award of a single-source expansion supplement to Community Action Partnership in Washington, DC, to create a new learning cluster focused on child poverty in rural communities and expanding access to multi-generational programs.

SUMMARY: The Administration for Children and Families (ACF), Office of Community Services (OCS), Division of State Assistance announces a single-source program expansion supplement in the amount of $50,000 to Community Action Partnership in Washington, DC, for $50,000. The supplement will support the creation of a new learning cluster focused on addressing child poverty in rural communities and tribal lands and increasing access to multi-generational programs. This effort supports a recent Administration initiative, Rural Impact. Rural Impact is a new effort, overseen by the White House Rural Council, to bring together federal agencies and public and private partners to support a multi-generational approach to investing in rural families, communities, and tribal places.


FOR FURTHER INFORMATION CONTACT: Seth Hassett, Division Director, Office of Community Services, 330 C Street SW., Washington, DC 20201. Telephone: 202–401–2333; Email: seth.hassett@acf.hhs.gov

SUPPLEMENTARY INFORMATION: The White House Rural Council recently launched Rural Impact, a new effort to bring together federal agencies and public and private partners to support a multi-generational approach to investing in rural families and communities. HHS is a member of the federal interagency team that supports this effort. Within HHS, the Administration for Children and Families, including the Office of Community Services, has a significant reach into rural America funding a wide range of services and projects that help rural families and communities.

Statutory Authority: This program is authorized by Sections 674(b)(2)(A) and 678A of the CSBG Act, as amended (42 U.S.C. 9903(b)(2)(A) and 9913).

Christopher Beach, Senior Grants Policy Specialist, Office of Administration.

[FR Doc. 2016–08506 Filed 4–12–16; 8:45 am]

BILLING CODE 4184–27–P
(FDA). The meeting will be open to the public.

**Name of Committee:** Circulatory System Devices Panel of the Medical Devices Advisory Committee.

**General Function of the Committee:** To provide advice and recommendations to the Agency on FDA’s regulatory issues.

**Date and Time:** The meeting will be held on May 24, 2016, from 8 a.m. to 6 p.m.

**Location:** Hilton Washington DC North/Gaithersburg, Salons A, B, C and D, 620 Perry Pkwy., Gaithersburg, MD 20877. The hotel’s phone number is 301–977–8900.

**Contact Person:** Evella Washington, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 1535, Silver Spring, MD 20993–0002, Evella.Washington@fda.hhs.gov, 301–796–6683, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area). A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

**Agenda:** On May 24, 2016, the committee will discuss, make recommendations and vote on information related to the premarket approval application regarding St. Jude Medical’s AMPLATZER Patent Foramen Ovale (PFO) Occluder. The AMPLATZER PFO Occluder is a percutaneously delivered permanent cardiac implant for PFO closure. The device is indicated for preventing recurrent ischemic stroke in patients who have had a cryptogenic stroke due to a presumed paradoxical embolism.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting link.

**Procedure:** Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before May 10, 2016. Oral presentations from the public will be scheduled on May 24, 2016 between approximately 1 p.m. and 2 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before April 28, 2016. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by May 2, 2016.

Persons attending FDA’s advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact AnnMarie Williams, AnnMarie.Williams@fda.hhs.gov, 301–796–5966, at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: April 8, 2016.

Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Meeting of the Presidential Commission for the Study of Bioethical Issues

**AGENCY:** Office of the Secretary, Office of the Assistant Secretary for Health, Presidential Commission for the Study of Bioethical Issues, Department of Health and Human Services.

**ACTION:** Notice of meeting.

**SUMMARY:** The Presidential Commission for the Study of Bioethical Issues (the Commission) will conduct its twenty fifth meeting on May 3, 2016. At this meeting, the Commission will reflect on the past, present, and future impact of national bioethics advisory bodies. Topics will include the history of national bioethics advisory bodies and their contributions to health policy, perspectives about similar bodies elsewhere, and discussion about what the future holds for groups like the Commission.

**DATES:** The meeting will take place May 3, 2016, from 9 a.m. to approximately 5 p.m.

**ADDRESSES:** Grand Hyatt Washington Hotel, 1000 H St. NW., Washington, DC 20001


**SUPPLEMENTARY INFORMATION:** Pursuant to the Federal Advisory Committee Act of 1972, Public Law 92–463, 5 U.S.C. app. 2, notice is hereby given of the twenty fifth meeting of the Commission. The meeting will be open to the public with attendance limited to space available. The meeting will also be webcast at www.bioethics.gov.

Under authority of Executive Order 13521, dated November 24, 2009, the President established the Commission. The Commission is an expert panel of not more than 13 members who are drawn from the fields of bioethics, science, medicine, technology, engineering, law, philosophy, theology, or other areas of the humanities or social sciences. The Commission advises the President on bioethical issues arising from advances in biomedicine and related areas of science and technology. The Commission seeks to identify and promote policies and practices that ensure scientific research,